High concentration of human immunodeficiency virus type 1 (HIV-1) RNA in plasma is an independent predictor of disease progression and development of AIDS [1] . A significant decrease in HIV-1 plasma RNA levels, measured with quantitative polymerase chain reaction (PCR), has been demonstrated following antiretroviral treatment with reverse transcriptase inhibitors, such as the nucleoside analogues zidovudine and didanosine [2, 3] . Besides infecting CD4 + lymphocytes, HIV-I infects cells in the central nervous system (CNS), mainly microglia and macrophages. HIV-1 spreads to the CNS at early stages of infection [4] , and a chronic progressive brain infection is established. Gradually increased cerebrospinal fluid (CSF) concentrations of neopterin and .Bz-microglobulin have been shown in the asymptomatic stage of HIV disease [5] . As a consequence of the chronic HIV-1 brain infection, neurologic deterioration and HIV -I-associated dementia are frequently found complications in late stages of HIV-1 infection. Thus, efficient treatment focused on the CNS infection is essential in an optimal anti-HIV treatment strategy.
In the present study, HIV-I RNA load was analyzed in CSF and serum before and after initiation of antiretroviral treatment with zidovudine or didanosine. Changes in virus load were compared with changes in neopterin and .Bz-microglobulin val-ues, which were used as markers of intrathecal immunoactivation.
Materials and Methods
Patients. Sixteen HIV-1-infected patients beginning single antiretroviral treatment between 1988 and 1994 at the Department ofInfectious Diseases, Goteborg University, participated in a study analyzing CSF before and during therapy. Their clinical characteristics are presented in table 1. The study group included 6 asymptomatic HIV-seropositive patients (CDC classification A2-A3 [6] ). One patient fulfilled the criteria for AIDS (CDC classification C3) because of a prior Pneumocystis carinii infection. Nine patients had symptomatic HIV infection not categorized as AIDS (CDC classification B2-B3); 6 of them had had oropharyngeal thrush, 2 had hairy leukoplakia, and 1 had a history of herpes zoster involving more than one dermatome. None of the patients had neurologic symptoms before or during the study.
In total, 21 treatment periods with antiretroviral therapy were analyzed for the 16 patients. Thirteen zidovudine treatment periods with a mean duration of8.9 months (range, 4-13) and 8 didanosine treatment periods with a mean duration of 8.4 months (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] were analyzed. Six patients had been randomized to singledrug treatment in a Scandinavian multicenter therapeutic study comparing single-drug zidovudine or didanosine therapy with alternating therapy, while the choice of therapy for 15 treatment periods was made on clinical grounds without randomization. Three patients changed from zidovudine to didanosine therapy, and 2 from didanosine to zidovudine therapy during the study. For 1 patient, the change from zidovudine to didanosine was made because of adverse hematologic effects. The other changes were not due to changes in clinical or laboratory status but were motivated by the increasing awareness that long-term single-drug therapy would increase the risk of developing viral resistance. patient with AIDS was in the group receiving zidovudine. Zidovudine and didanosine were administered orally in daily dosages of 400-600 mg and 300-500 mg, respectively.
Ten of the patients had previously participated in a study analyzing the impact of antiretroviral therapy on intrathecal immunoactivation [7] .
Lumbar punctures were performed before and after each change in therapy in a standardized manner, whereby~20-25 mL ofCSF was collected in portions. After cell counting, the first 12-mL portion of CSF was centrifuged and immediately stored in smaller fractions at -70°C, without thawing until analyzed. None of the samples analyzed had a CSF red blood cell count > 30 cells/mnr'.
HIV-I RNA in cell-free CSF and serum was quantified using a commercially available quantitative polymerase chain reaction (Amplicor HIV Monitor, Roche Diagnostic System; Hoffman-La Roche, Basel) and run according to the manufacturer's protocol. To avoid effects of between-assay variation, all samples from each patient were run in parallel in the same test. HIV RNA levels were expressed as 10glO RNA copies per milliliter of CSF or serum. In samples in which HIV RNA could not be detected, the levels were approximated to 2.30 10glO (200 copies/mL), which was the limit of detection of the assay. Neopterin was measured by a commercially available RIA (IMMU test; Henning-Berlin, Berlin), and ,8rmicro-globulin by an ELISA. Normal laboratory reference values were <8.8 nmollL in serum and <4.2 nmol/L in CSF for neopterin, and <2.4 mg/L in serum and <2.2 mg/L in CSF for ,82-microglobulin. The peripheral blood CD4+ cell count was measured by direct immunofluorescence in a flow cytometer.
Statistics. Paired pre-and posttreatment values in each treatment group were compared by using the Wilcoxon signed rank test. Comparisons of zidovudine treatment periods with didanosine treatment periods were not statistically evaluated because patients were not randomly allocated to all treatment schedules. Spearman's rank correlation coefficient was used for evaluations of correlations.
Results
Changes in CSF and serum levels of HIV RNA, neopterin, and ,Brmicroglobulin, and in peripheral blood CD4 + cell counts after initiation of zidovudine or didanosine are shown in table 2. CSF HIV RNA levels decreased in 12 of 13 patients and remained unchanged in 1 after initiation of zidovudine. The mean reduction was 1.0510g lO (-91%, P < .01), from 3.95 to 2.90 10g lO • In 2 of 8 treatment periods with didanosine, HIV RNA could not be detected in the CSF in either pre-or posttreatment samples. Those 2 treatment periods were therefore excluded from the calculations. CSF HIV RNA levels decreased in 3 of 6 didanosine treatment periods and increased in three. The mean change was +0.13 log., (not significant). HIV RNA levels decreased to undetectable CSF concentrations «200 copies/mL) during 4 zidovudine treatment periods but in none of the didanosine treatment periods. The 3 patients in whom CSF HIV RNA levels decreased during didanosine treatment had not received previous therapy, while the 3 with increased levels had been switched from zidovudine to didanosine.
In contrast to the CSF levels, serum HIV RNA levels were not significantly changed following the initiation of zidovudine treatment, whereas serum HIV RNA levels decreased from 4.24 to 3.71 10gIO RNA copies/mL (-0.53 10glO, P < .05) after initiation of didanosine treatment. Concentrations of CSF neopterin decreased from 28.0 to 12.0 nmollL (-57%, P < .01), and CSF ,Brmicroglobulin concentrations decreased from 2.83 to 1.89 mg/L (-33%, P < .01) after zidovudine treatment.
No significant changes in CSF neopterin or ,Brmicroglobulin concentrations followed didanosine treatment. The serum neopterin concentrations decreased after both zidovudine (from 24.7 to 19.3 nmol/L [-22%, P < .05]) and didanosine (from 25.2 to 18.5 nmol/L [-27%, P < .05]) treatment, as did the serum ,Brmicroglobulin, with 20% (P < .01) after initiation of zidovudine and 12% (P < .05) after didanosine. No significant changes were found in the CD4 + cell count after either zidovudine or didanosine treatment.
A significant correlation was found between the antiretrovirus-induced changes in CSF HIV RNA and the changes in CSF neopterin (r s = .81, P < .001) and CSF ,B2-microglobulin (r s = .83, P < .001). There were no significant correlations between Table 2 . Changes in cerebrospinal fluid (CSF) and serum levels of HIV RNA, neopterin, and ,62-microglobulin and peripheral blood CD4+ cell counts before and after 3-13 months of treatment with zidovudine (AZT) or didanosine (ddI).
AZT treatment (n = 13) ddI treatment (n = 8) .37). Neither were any significant correlations found between changes in CSF and serum HIV RNA levels (r s = -.29, P = .11).
Discussion
Optimal anti-HIV treatment must take the CNS into account. Clinically, zidovudine treatment reduces the risk of development of AIDS dementia complex [8] , while no such benefit has been associated with didanosine treatment [9] . Neuropathologically, the incidence of HIV encephalitis was decreased by zidovudine treatment [10] , but it has been demonstrated that switching from zidovudine to didanosine also is protective against HIV encephalitis [11] . We have, in an earlier study [7] , shown that intrathecal immunoactivation is reduced by zidovudine but not by didanosine.
In the present study, CSF HIV-l RNA levels were reduced following zidovudine treatment, while no significant reduction followed didanosine treatment. Since the treatment periods were nonrandomized, it was not feasible to make statistical comparisons between the treatment regimens. Instead, paired pre-and posttreatment samples within each group were compared. The interpretation of the observations must be cautious, since the number of patients in this study is small, and 5 of 21 observations are repeat measures of patients who changed therapy. However, a decrease in CSF HIV RNA in all but 1 zidovudine treatment period, in which the concentration remained unchanged, clearly shows the benefit of zidovudine for HIV infection in the CNS. Following didanosine treatment, only 3 of 3 evaluable treatment periods (2 had nondetectable HIV RNA levels before initiation of treatment) resulted in reduced HIV RNA levels, while increased values were found after 3 treatment periods. These results suggest that didanosine has a poor anti-HIV effect in the CNS. However, minor effects on CSF HIV RNA by didanosine could not be excluded because all 3 therapeutically inexperienced patients had decreased HIV RNA levels. Differences in ability to penetrate the blood-brain barrier, which zidovudine penetrates sufficiently, while didanosine shows inferior penetration capacity [12, 13] , could explain the difference found in CNS effects between the two drugs.
In the present study, sera, not plasma, were used for quantitative HIV RNA measurements. Conrad et al. [14] compared plasma and serum levels of HIV RNA. The levels were slightly lower in serum than in plasma (median difference, 10%), which may result in more false-negative results in analyses of serum when the copy number is very small. In our study, however, all serum samples were positive, and there should be no differences in the results comparing treatment-induced changes in plasma or serum.
The mean serum level of HIV RNA was not significantly changed by zidovudine treatment in samples collected (mean, 8.9 months; range, 4-13) after initiation of zidovudine treatment. This lack of demonstrable reduction in serum HIV RNA by zidovudine treatment is probably a consequence of the time of sampling, since plasma HIV RNA, after an initial decrease, returns to baseline levels within 12 months [2] . However, the lower CSF HIV RNA levels following zidovudine treatment were maintained for > 12 months in 4 patients analyzed. The mean serum HIV RNA level was significantly decreased by didanosine. This finding is in accordance with those ofYerly et al. [3] , who recently showed that after 18-24 months of didanosine therapy, the HIV RNA level remained decreased.
In the present study, changes in CSF HIV RNA levels correlated with changes in CSF neopterin and ,Brmicroglobulin concentrations following antiretroviral treatment. This might suggest that neopterin and ,BTmicroglobulin, which are simple, inexpensive surrogate markers for HIV progression, still have a role as monitors of therapy effects in the CNS, provided no concurrent CNS opportunistic infection is present. However, in serum there were no correlations between changes in HIV RNA and neopterin or ,Brmicroglobulin concentrations. Furthennore, no correlations were found between changes in HIV RNA serum and eSF levels, indicating that there is no continuous major exchange of free virus between serum and eSF. This proposal of compartment barrier is strengthened by our earlier findings on differences in mutation patterns of HIV reverse transcriptase in serum and eSF of zidovudine-treated patients [15] .
We conclude that zidovudine is a potent reducer of eNS virus load and that zidovudine should be included in combination antiretroviral treatment regimens for long-term neuroprotection.
